InsidersTradesSigma
Track the GALECTIN THERAPEUTICS INCORPORATED share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €405.4m. The latest transaction was disclosed on 29 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Harold Shlevin. Every trade is accessible without an account.
Analysts rate GALECTIN THERAPEUTICS INCORPORATED Strong Buy (bullish), based on 1 analysts. Average price target: US$11.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
GALECTIN THERAPEUTICS INCORPORATED 是一家生物技术公司，专注于通过靶向半乳糖凝集素（参与各种病理过程的蛋白质）来开发严重疾病的治疗方法。